Scarica l'app Stockscreener
7.58
2.19%
-0.17
Dopo l'orario di chiusura:
7.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - Simply Wall St
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
What 4 Analyst Ratings Have To Say About Ocular Therapeutix - Benzinga
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - Nasdaq
Ocular's Axpaxli May Take Wet AMD Market Share, RBC Says -March 18, 2025 at 11:38 am EDT - Marketscreener.com
RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
Ocular rises as Needham issues new Buy on lead candidate - MSN
When (OCUL) Moves Investors should Listen - Stock Traders Daily
Ocular Therapeutix (OCUL) Stock Movement Driven by Analyst Cover - GuruFocus.com
Why Ocular Therapeutix Was Bumping Higher This Week - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - AOL
Needham Initiates Ocular Therapeutix at Buy With $15 Price Target -March 11, 2025 at 07:30 am EDT - Marketscreener.com
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq
Ocular Therapeutix initiated with a Buy at Needham - TipRanks
Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada
Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Australia
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World
Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha
Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World
Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire
Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - MSN
Truist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Traders Purchase High Volume of Call Options on Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus.com
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix price target lowered to $19 at Citizens JMP, buy on weakness - TipRanks
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
New York State Common Retirement Fund Boosts Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback - MSN
Ocular Therapeutix Reports Fourth Quarter and Full Year 2024 Revenue Growth - Vision Monday
Ocular Therapeutix Inc (OCUL) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings - Defense World
Ocular Therapeutix Inc. Faces Operational Risks Amid Regulatory Delays and Government Disruptions - TipRanks
Ocular Therapeutix Reports 2024 Financial Results and Progress - TipRanks
Ocular Therapeutix Earnings Call Highlights Progress and Challenges - TipRanks
Ocular Therapeutix: Q4 Earnings Snapshot - CTPost
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Earnings call transcript: Ocular Therapeutix Q4 2024 misses EPS forecast - Investing.com India
Earnings call transcript: Ocular Therapeutix Q4 2024 misses EPS forecast By Investing.com - Investing.com Australia
BofA cuts Ocular Therapeutix target to $17, maintains buy By Investing.com - Investing.com UK
Ocular Therapeutix shares tumble on earnings miss By Investing.com - Investing.com South Africa
Ocular Therapeutix shares tumble on earnings miss - Investing.com
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates - MSN
Ocular Therapeutix Shares Drop After Wider-Than-Expected 4Q Loss - MarketWatch
Ocular Therapeutix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):